{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:57:32Z","timestamp":1760299052364},"reference-count":30,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Clin Exp Hematopathol","JCEH"],"published-print":{"date-parts":[[2014]]},"DOI":"10.3960\/jslrt.54.197","type":"journal-article","created":{"date-parts":[[2014,12,14]],"date-time":"2014-12-14T23:18:21Z","timestamp":1418599101000},"page":"197-204","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of Molecular Response at 1 or 3 Months after the Initiation of Dasatinib Treatment Can Predict an Improved Response to Dasatinib in Imatinib-Resistant or Imatinib-Intolerant Japanese Patients with Chronic Myelogenous Leukemia during the Chronic Phase"],"prefix":"10.3960","volume":"54","author":[{"given":"Koiti","family":"Inokuchi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eri","family":"Matsuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuteru","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Shinagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikashi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Wakita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuji","family":"Kozai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukari","family":"Shirasugi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shin","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osamu","family":"Iwase","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Oba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hisashi","family":"Sakamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Wong S, Witte ON: The BCR-ABL story: bench to bedside and back. Annu Rev Immunol 22:247-306, 2004","DOI":"10.1146\/annurev.immunol.22.012703.104753"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, <i>et al<\/i>.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042, 2001","DOI":"10.1056\/NEJM200104053441402"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, <i>et al<\/i>.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001","DOI":"10.1056\/NEJM200104053441401"},{"key":"4","unstructured":"4 Kantarjian HM, O&apos;Brien S, Cortes JE, Smith TL, Rios MB, <i>et al<\/i>.: Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 8:2167-2176, 2002"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Druker BJ, Guilhot F, O&apos;Brien SG, Gathmann I, Kantarjian H, <i>et al<\/i>.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 355:2408-2417, 2006","DOI":"10.1056\/NEJMoa062867"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, <i>et al<\/i>.: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001","DOI":"10.1126\/science.1062538"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, <i>et al<\/i>.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002","DOI":"10.1016\/S1535-6108(02)00096-X"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hochhaus A, Hughes T: Clinical resistance to imatinib: mechanisms and implications. Hematol Oncol Clin North Am 18:641-656, 2004","DOI":"10.1016\/j.hoc.2004.03.001"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Hochhaus A, Kreil S, Corbin AS, La Ros\u00e9e P, M\u00fcller MC, <i>et al<\/i>.: Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia.16:2190-2196, 2002","DOI":"10.1038\/sj.leu.2402741"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschl\u00e4gel U, <i>et al<\/i>.: P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 18:401-408, 2004","DOI":"10.1038\/sj.leu.2403257"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Thomas J, Wang L, Clark RE, Pirmohamed M: Active transport of imatinib into and out of cells: implications for drug resistance. Blood 104:3739-3745, 2004","DOI":"10.1182\/blood-2003-12-4276"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Dai Y, Rahmani M, Corey SJ, Dent P, Grant SA: A Bcr\/Abl-independent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J Biol Chem 279:34227-34239, 2004","DOI":"10.1074\/jbc.M402290200"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, <i>et al<\/i>.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 101:690-698, 2003","DOI":"10.1182\/blood.V101.2.690"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 O&apos;Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, <i>et al<\/i>.: <i>In vitro<\/i> activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 65:4500-4505, 2005","DOI":"10.1158\/0008-5472.CAN-05-0259"},{"key":"15","unstructured":"15 Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, <i>et al<\/i>.: Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood 109:5143-5150, 2007"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, <i>et al<\/i>.: Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 109:2303-2309, 2007","DOI":"10.1182\/blood-2006-09-047266"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Guilhot F, Apperley J, Kim DW, Bullorsky EO, Baccarani M, <i>et al<\/i>.: Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood 109:4143-4150, 2007","DOI":"10.1182\/blood-2006-09-046839"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Cortes J, Rousselot P, Kim DW, Ritchie E, Hamerschlak N, <i>et al<\/i>.: Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis. Blood 109:3207-3213, 2007","DOI":"10.1182\/blood-2006-09-046888"},{"key":"19","unstructured":"19 Ottmann O, Dombret H, Martinelli G, Simonsson B, Guilhot F, <i>et al<\/i>.: Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood 110:2309-2315, 2007"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Mauro MJ, Baccarani M, Cervantes F, Lipton JH, Matloub R, <i>et al<\/i>.: Dasatinib 2-year efficacy in patients with chronic-phase chronic myelogenous leukemia (CML-CP) with resistance or intolerance to imatinib (START-C). J Clin Oncol 26 (Suppl 18):7009a, 2008","DOI":"10.1200\/jco.2008.26.15_suppl.7009"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Yoshida C, Fletcher L, Ohashi K, Wakita H, Kumagai T, <i>et al<\/i>.: Harmonization of molecular monitoring of chronic myeloid leukemia therapy in Japan. Int J Clin Oncol 17:584-589, 2012","DOI":"10.1007\/s10147-011-0328-x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Kumagai T, Matsuki E, Inokuchi K, Ohashi K, Shinagawa A, <i>et al<\/i>.: Relative increase in lymphocytes from as early as 1 month predicts improved response to dasatinib in chronic-phase chronic myelogenous leukemia. Int J Hematol 99:41-52, 2014","DOI":"10.1007\/s12185-013-1483-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Inokuchi K, Shinohara T, Futaki M, Hanawa H, Tanosaki S, <i>et al<\/i>.: Establishment of a cell line with variant BCR\/ABL breakpoint expressing P180BCR\/ABL from late-appearing Philadelphia-positive acute biphenotypic leukemia. Genes Chromosomes Cancer 23:227-238, 1998","DOI":"10.1002\/(SICI)1098-2264(199811)23:3<227::AID-GCC4>3.0.CO;2-3"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Inami M, Inokuchi K, Nakayama K, Tamura H, Shimada T, <i>et al<\/i>.: Simultaneous novel BCR-ABL gene mutation and increased expression of BCR-ABL mRNA caused clinical resistance to STI571 in double-Ph-positive acute biphenotypic leukemia. Int J Hematol 78:173-175, 2003","DOI":"10.1007\/BF02983390"},{"key":"25","unstructured":"25 M\u00fcller MC, Cortes JE, Kim DW, Druker BJ, Erben P, <i>et al<\/i>.: Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood 114:4944-4953, 2009"},{"key":"26","unstructured":"26 Milojkovic D, Apperley JF, Gerrard G, Ibrahim AR, Szydlo R, <i>et al<\/i>.: Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients. Blood 119:1838-1843, 2012"},{"key":"27","unstructured":"27 Shah NP, Guilhot F, Cortes JE, Schiffer CA, Le Coutre P, <i>et al<\/i>.: Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of phase 3 study. Blood 123:2317-2324, 2014"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Hanfstein B, M\u00fcller MC, Hehlmann R, Erben P, Lauseker M, <i>et al<\/i>.: Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia 26:2096-2102, 2012","DOI":"10.1038\/leu.2012.85"},{"key":"29","unstructured":"29 Fujisawa S, Nakamae H, Ogura M, Ishizawa K, Taniwaki M, <i>et al<\/i>.: Efficacy and safety of dasatinib versus imatinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia (CML-CP): Subset analysis of the DASISION trial with 2-year follow-up. Int J Hematol 99:141-153, 2014"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Shah NP, Kim DW, Kantarjian H, Rousselot P, Llacer PED, <i>et al<\/i>.: Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica 95:232-240, 2010","DOI":"10.3324\/haematol.2009.011452"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","deposited":{"date-parts":[[2021,5,20]],"date-time":"2021-05-20T19:46:47Z","timestamp":1621540007000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/54\/3\/54_197\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.54.197","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014]]}}}